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Abstract
Objective: The aim of the study was to assess the success and complications of vaginal mesh surgery performed
in 250 successive cases. Design: This study had a retrospective design. Materials and Methods: An analysis was
performed of vaginal mesh surgery for complaints of stage II or greater pelvic organ prolapse (POP) from
September 2008 to November 2010. A composite score that included subjective criteria of absence of a both-
ersome bulge, and objective criteria based upon Pelvic Organ Prolapse–Quantification (POP-Q) stage < II and no
re-interventions was used to assess treatment success. Results: Transvaginal mesh surgery was performed in 250
subjects (age: 64.40– 11.26 years, body mass index [BMI]: 28.96– 5.38 kg/m2) for POP. Ten (4.0%) anterior
mesh surgeries, 69 (27.6%) posterior mesh surgeries, and 171(68.4%) total mesh surgeries were performed in
subjects with stage II or greater degrees of prolapse. Stage II prolapse was noted in 61 (24.4%) subjects, 154
(61.6%) had stage III, and 35 (14.0%) had stage IV prolapse. The mean follow-up was 13 months, and 222
(88.8%) patients were seen at least 12 months post-surgery. The composite success score was 89.2%. Pure
anatomic success based upon POP-Q< stage II was 94.1%. Mean operative time was 119.71– 41.58 minutes.
Mean intraoperative blood loss was 109.28– 110.89 mL. There were 12 (5.4%) cases of mesh exposure in the
vagina. There were no visceral injuries or mesh erosions. The incidence of de novo dyspareunia was 15.8%.
Conclusions: Transvaginal mesh surgery for POP is safe and effective, with few postoperative morbidities when
performed by an experienced pelvic floor surgeon. ( J GYNECOL SURG 30:134)
Introduction
United States Census Bureau projections estimatethat as many as 9,200,000 women in the United States
will have prolapse by the year 2050, and, as may be expected,
the demand for services to care for pelvic floor disorders is
also estimated to increase by 45% by the year 2030.1 The
lifetime risk of undergoing surgery for pelvic organ prolapse
(POP) in the general female population up to the age of 85
years has recently been reported to be as high as 19%–20%.2
The cost of treating POP is also significant, because the
direct costs of prolapse surgery were estimated to be $1,012
million (in 1997). Furthermore, women with POP have an
impaired quality of life (QoL), are more likely to be self-
conscious, and are less likely to feel physically and sexually
attractive than normal controls.3 Therefore, POP is not only
a highly prevalent gynecologic condition, but its incidence
also is exponentially increasing with escalating burden on
decreasing health care resources. For all of these reasons,
there is a need for surgical procedures that are minimally
invasive with minimal complications and risk, and that offer
low recurrence with high rates of long-term success.
Traditional non-mesh repairs have been hampered by high
rates of recurrence. Weber et al. noted a high recurrence rate
of 54%–70%, especially of the anterior vaginal wall.4 Fur-
thermore, Olsen et al. retrospectively observed that a woman
has a 29% chance of re-operation for pelvic organ prolapse
following an index surgery.5 This has led to an increasing
push to incorporate synthetic mesh in POP repair. A recent
meta-analysis encompassing 30 studies with 2653 patients
calculated the objective success rates to be 87%–95% for
several different commercial POP mesh kits.6
However, on July 13, 2011, the United States Food and
Drug Administration (FDA) released a second Safety
Communication in response to the reporting of more com-
plications associated with transvaginal mesh placement.7
The FDA update stated that adverse events for POP mesh
repair are not rare, as was previously reported, and brought
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into question the relative effectiveness of meshed versus
unmeshed repairs. Vaginal mesh surgery has its unique risks
for complications, and the anatomic success may not nec-
essarily indicate a functional or subjective improvement in
outcomes.
This study reports on the use of a 50-50 blend mesh, Pro-
lift+M (Ethicon Inc., Somerville, NJ) transvaginal mesh
that contains poliglecaprone-25 knitted with polypropylene
(PP-PG). The poliglecaprone-25 (Monocryl) is absorbed
after 3 months, leaving a lower burden of mesh in the vagina,
decreasing from 57 g/m2 to 31 g/m2 (data on file: Ethicon Inc.,
Somerville, NJ). The pore size following absorption increases
from 2.5 mm to 3.5 mm. Preclinical studies have reported
that the greater distance between pores resists the ability
of ‘‘bridging fibrosis,’’ thereby leading to a compliant and
flexible scar tissue that mimics natural tissue mobility.8
This study was conducted in the first 250 successive pa-
tients who underwent the PP-PG vaginal mesh surgery for
genital organ prolapse. The primary objective was to assess
success based upon both subjective and objective criteria,
and the secondary objective was to assess complications and
also the impact of surgery on urinary incontinence, vaginal
healing, and sexual function.
Materials and Methods
This is a retrospective study performed in the first 250
consecutive cases of POP managed with the PP-PG system
from September 2008 to November 2010. The study was
approved by the Institutional Review Board of Wayne State
University. Ethicon Inc., the manufacturer of PP-PG mesh
system, had no influence over the study, and no external
funding was obtained for the study.
The inclusion criterion was having undergone a vaginal
mesh surgery for complaints of stage II or greater prolapse.
The exclusion criteria included not completing the validated
questionnaires.
All definitions and descriptions conformed to the stan-
dards recommended by the International Continence So-
ciety. The anatomical outcome was assessed with the Pelvic
Organ Prolapse–Quantification (POP–Q) score, which is
described by the International Continence Society as a re-
liable and specific method to measure pelvic organ support.
The subjects completed validated questionnaires at pre-
operative and postoperative visits. The Pelvic Floor Distress
Inventory–20 (PFDI–20) was used as a symptom-specific
questionnaire for pelvic organ prolapse. The PFDI-20 sub-
scores include Pelvic Organ Prolapse Distress Inventory
(POPDI), ColoRectal Anal Distress Inventory (CRADI) and
the Urogenital Distress Inventory–6 (UDI–6).9,10 The Med-
ical Epidemiological and Social aspects of Aging (MESA)
forms were used to assess associated urinary incontinence
symptoms.11 Scores of the PFDI–20 were calculated in a
simple additive fashion, in which a higher score indicated
more distressful symptoms. The Dindo scale was used to
classify postoperative complications.12
Success was defined by a composite score that comprised
the following:
1. POP-Q stage < II
2. PFDI Question 3 ‘‘Do you usually have a bulge or
something falling out that you can see or feel in the
vaginal area?’’ Answered No.
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3. No reinterventions for POP such as pessary or surgery
of either the treated or the untreated compartment.
In order for a subject to be considered to have had a
successful outcome, that subject would have to have met
each of the abovementioned criteria. Anatomic success
(POPQ stage < II) but continued perception of a bothersome
bulge constituted a failure.
All eligible subjects underwent a detailed urogyneco-
logic history and examination including a POP-Q system
assessment.
All subjects with an anterior vaginal wall prolapse, symp-
toms of urinary incontinence, or voiding dysfunction under-
went urodynamic testing that was conducted in a standardized
fashion. Occult stress urinary incontinence (SUI) was as-
sessed by elevating the prolapsed anterior vaginal wall to
simulate postsurgical repair. Intraoperative cystourethroscopy
was performed in all subjects with anterior or total mesh
surgeries or undergoing a concomitant sling procedure.
The surgical procedure was performed as per the tech-
nique described by the Trans-Vaginal Mesh group.13 For
total vaginal mesh procedures, the mesh was kept intact as
one piece and taken around an intact 2–3 cm apical bridge
for post-hysterectomy vault prolapses. If the uterus was
present, the mesh was cut into two pieces and the two halves
were attached to the anterior and posterior aspect of the
cervix, respectively. A permanent 2-0 prolene suture was
used to anchor the mesh to the cervix.
The preoperative versus postoperative POPQ values were
analyzed with the Statistical Package for the Social Sciences
Version 20 (SPSS Inc. Chicago, IL) and were compared
using paired sample t test for all stages. The comparisons
between preoperative and postoperative questionnaire scores
were performed with the same method.
Results
Vaginal mesh surgery was performed in 250 patients from
September 2008 to November 2010. This was the initial
group of women to undergo this partially absorbable mesh
procedure, and 222 (88.8%) patients were seen at least 12
months post-surgery. The mean follow-up was 13.47– 3.38
months with a range of 7–31 months. Total vaginal mesh was
performed in 171/250 (68.4%) cases, anterior mesh surgery
was performed in 10/250 (4%), and posterior mesh surgery
was performed in 69/250 (27.6%). Detailed demographics
and surgical characteristics are presented in Table 1. Stage II
prolapse was noted preoperatively in 61/250 (24.4%) sub-
jects, stage III prolapse was noted in 154/250 (61.6%), and
stage IV prolapse was noted in 35/250 (14.0%) subjects.
Preoperative and postoperative POPQ information is listed
in Tables 2 and 3.
The composite success score based upon determined para-
meters was 89.2%. Anatomic success (POP-Q stage < II) was
noted in 94.1% cases, whereas the lack of perception of a
vaginal bulge was noted in 92.8%. There was only one re-
operation for prolapse, and this was the result of apical failure
and necessitated a hysterectomy with sacrospinous ligament
suspension. This patient had undergone a total vaginal mesh
procedure.
All patients who had intraoperative cystoscopies demon-
strated normal findings without any injury. The mean blood
loss was 109.3 mL (standard deviation – 111 mL) and none
of the patients received blood transfusions. Most patients
were discharged home after an overnight stay, with a mean
of 1.14 – 0.51 days. Normal voiding function at discharge
was noted in 226/250 (90.4%) patients. The remaining 24
patients were sent home with a Foley catheter, which was
successfully removed in 19 patients at the first attempt in the
office on the 7th postoperative day, as per protocol. Of these
24 patients sent home with a Foley catheter, 17 (70.8%)
patients had undergone a concomitant suburethral sling
procedure. The remaining 5 patients failed the attempt, and
were taught self-catheterization, which they eventually dis-
continued within 2 weeks. None of the patients had any
lingering voiding dysfunction at their 1 year follow-up visit.
Voiding dysfunction was defined as any subjective symp-
toms of difficulty urinating or elevated post-void residuals.
Results of preoperative and postoperative validated ques-
tionnaire scores are listed in Table 4.
Mesh exposure as defined as mesh visible or palpable on
vaginal exam or felt by patient or partner was noted in 5.4%
(12/222) subjects. Of these patients, 3 (25%) underwent
excision of the exposed mesh, 2 in the operating room (OR)
and 1 in the office. The other patients (75%) were managed
expectantly. The mean area of exposure was 1.5 cm. There
were no erosions into the neighboring organs such as the
bladder or the bowel. There were 5 cases of recurrent uri-
nary tract infections (UTIs), and all these patients underwent
a normal cystoscopy performed to rule out any mesh erosion
into the bladder or the urethra. There was only 1 patient
(0.4%) with de novo stress urinary incontinence. The current
authors did not look systematically for vaginal retraction
during the period of the study. However, there was no
change in the total vaginal length (TVL) noted from the
preoperative to the postoperative values.
Table 2. Pre-Op and Post-op POPQ Stages
Total Posterior Anterior All
POP-Q
Stage
Pre-op
n = 171
Post-op
n = 154
Pre-op
n = 69
Post-op
n = 60
Pre-op
n = 10
Post-op
n= 8
Pre-op
n = 250
Post-op
n = 222
0 0 95 0 33 0 6 0 134
I 0 52 0 23 0 2 0 77
II 16 6 39 3 6 0 61 9
III 121 1 30 1 3 0 154 2
IV 34 0 0 0 1 0 35 0
op, operative; POP-Q, Pelvic Organ Prolapse–Quantification.
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De novo dyspareunia was noted in 14/95 (14.7%) patients.
In this study, only 95 women were sexually active post-
operatively. Twelve women, who had not been active pre-
operatively, became active postoperatively, and 1 of them
complained of dyspareunia. If she is taken into account, the
de novo dyspareunia rate is 15/95, or 15.8%.
The Dindo classification was as follows:
 Grade I: 27 subjects (15 de novo dyspareunia, 12 mesh
exposures)
 Grade II: 10 subjects (5 UTIs, 5 straight catheteriza-
tions for 1 week)
 Grade IIIa: 1 subject (1 mesh revision in office)
 Grade IIIb: 4 subjects (2 mesh revisions in OR, 2
perineal revisions in OR)
 There were no Dindo Grade IV/V complications
The complications information is listed in Table 5.
Discussion
This retrospective cohort study of the first 250 successive
patients treated with the second generation partially ab-
sorbable PP-PG system for pelvic organ prolapse shows
good success in both the anatomic and functional domains.
Definition of treatment success that includes improvement
of vaginal bulge perception and absence of any new unto-
ward side effects is more meaningful to a patient than just an
anatomic cure.14 In this study, subjective improvement was
noted in 92.8% cases.
A total of 222 patients were followed up for at least 12
months, providing at least a short- term evaluation. A
comprehensive review article15 and a long term study16 have
noted that most complications including mesh exposures
become evident by 12 months. The reoperation rate for
prolapse in this study was 0.4% (1/222) and is less than
the 2.3%–4% reported in studies that provided a minimum
1 year follow-up.16,17 However, one of these studies16 in-
volved > 500 patients with a 3 year follow-up, unlike this
one, which is only a 12 month short-term study. There were
no injuries in this study. These results are consistent with
most published reports on PP-PG mesh repair, in which the
rates of visceral or vascular injuries ranged from 0 to
6.6%.18,19 The mesh exposure rate of 4.8% was similar to
the 4% rate noted by Altman et al.20 de Landsheere et al.,16
also in a large 500 case study followed for at least 3 years,
noted a mesh exposure rate of only 2.7%. Moreover, most of
their exposures presented within the 1st year after surgery.
This incidence is lower than the 10.3% for all synthetic
mesh procedures reported by a systematic review by Abed
et al.15 Nonetheless, it is comparable to the 3.4% reported
rate after sacrocolpopexy in the review of Nygaard et al.21
Only 25% of the mesh exposures cases in the present study
required a minor surgical intervention to correct them. Most
were managed expectantly. This is similar to the report of
Withagen et al.22
The incidence of anal sphincteroplasty in this series
apparently seems high (21.6%). In this series, anal sphinc-
teroplasty was based on a patient’s history of anal inconti-
nence, the PFDI questionnaire pertaining to the bowel
function, findings of anal sphincter disruption noted on
clinical examination as a dove-tail sign, or a two finger
rectal examination, and confirmed by anorectal manometry
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and anal ultrasound. Patients were counseled about the
findings and surgery was based on the severity of symptoms
and patient desire. It is being increasingly realized that
women with other pelvic floor disorders may have a higher
incidence of fecal incontinence (35%–50%).23 Moreover,
this is an underreported condition, and validated question-
naires unmask its presence as a bothersome symptom.24
There was only one case of de novo SUI (0.4%). This is in
contrast to the study by Cho et al.,25 who noted a de novo
SUI rate of 29.4%. This is despite the fact that they, too,
reduced the bulge with sponge sticks during preoperative
urodynamics to assess for occult SUI. It is possible that their
prolapse cases were very advanced, and hence may have
been difficult to reduce accurately preoperatively.
The incidence of de novo dyspareunia in this study was
15.8%. This is similar to the dyspareunia rate following
traditional prolapse repair (14.5%–36.1%), and a recent
retrospective study reported a similar rate (16.7%) following
repair with the original polypropylene mesh.26 Although we
did not specifically look at vaginal mesh retraction, there
was no statistically significant decrease in the TVL from
before surgery to the 12 month postoperative visit. More-
over, as PP-PG is a partially absorbable mesh, it may de-
crease the risk of bridging fibrosis, and, therefore, scar tissue
formation.27
The proportion of the combined (anterior and posterior)
vaginal mesh procedures (68%) to all mesh repairs was high
in this study. This is mainly because the primary function of
the posterior part of the total mesh was to support the
vaginal apex to the sacrospinous ligaments more than to
correct a rectocele. Also, several subjects in the study un-
derwent a mesh hysteropexy, and this required a bilateral
(anterior and posterior) cervical attachment for proper sup-
port. Moreover, care was taken to preoperatively identify
small contralateral prolapses that in the past have resulted in
failures of the unsupported contralateral compartment.28
This is similar to the findings of Withagen et al.,19 who
noticed a high risk of recurrence of the contralateral un-
supported compartment following vaginal mesh surgery.
Therefore, this study shows that if mesh is to be used, it
should be planned correctly, and the contralateral apparently
supported wall should be scrutinized carefully. Moreover,
the value of the apex in total vaginal support is paramount.
The anterior PP-PG mesh attaches laterally to the obturator
internus and does not provide good DeLancey level I sup-
port as compared with the posterior arm, which attaches to
the sacrospinous ligament.
Even though the PP-PG is no longer available, this study
still helps in understanding the role of mesh in prolapse
surgery. Moreover, the properties of PP-PG, such as the
tensile strength, pore size, material type (type IA polypro-
pylene), and weight are similar to those of the mesh systems
still available today.
The strengths of this study are the enrollment of all suc-
cessive patients who underwent the surgery during the 2
year time period, at least 1 year of follow-up, restriction to a
single mesh kit, and the use of subjective and objective
validated criteria to assess success, using validated outcome
measures.
The weaknesses are those inherent to a retrospective
design, mainly the lack of a control group. The POPQ as-
sessments were performed by the primary surgeons (S.K.,
C.W.), and not by an independent observer. Although this
could introduce an element of bias, the highly favorable
patient subjective outcome supports the main results.
Conclusions
On July 13, 2011, the FDA released a second Safety
Communication in response to the reporting of more com-
plications associated with transvaginal mesh placement,
stating that adverse events for POP mesh repair are not rare.7
Table 4. Preoperative Versus Postoperative Validated Questionnaire Scores
Pre-operative score Post-operative score p-Value
POPDIa 41.3 – 26.7 (0 to 100) 8.1 – 13.2 (0 to 80) < 0.000
CRADIa 25.9 – 21.4 (0 to 89.3) 12.9 – 14.0 (0 to 87.5) < 0.000
UDI-6a 37.1 – 27.6 (0 to 100) 14.2 – 16.9 (0 to 79) < 0.000
PFDI-20 SUMMARYa 104.1 – 61.6 (0 to 281.3) 35.2 – 34.5 (0 to 227.9) < 0.000
MESA STRESSa 30.0 – 28.9 (0 to 100) 14.8 – 19.2 (0 to 100) < 0.000
MESA URGEa 23.4 – 23.9 (0 to 88.9) 15.8 – 18.2 (0 to 83.3) < 0.000
aMean– standard deviation (minimum to maximum).
POPDI, Pelvic Organ Prolapse Distress Inventory; CRADI, Colo-Rectal Anal Distress Inventory; UDI-6, Urinary Distress Inventory-6;
PFDI-20, Pelvic Floor Distress Inventory-20; MESA, Medical Epidemiological and Social aspects of Aging.
Table 5. Number of Intraoperative
and Postoperative Complications
Intraoperative complications Number
Bladder perforation 0
Rectal perforation 0
Ureteral injury 0
Blood transfusion 0
Postoperative Complications
Recurrent urinary tract infection 5
Voiding difficulty 7
De novo stress urinary incontinence 1
De novo urge urinary incontinence 1
De novo fecal incontinence 2
Vaginal mesh erosion 0
Vaginal mesh exposure 12
Infection of mesh 0
Fistula 0
De novo dyspareunia 15
Recurrence of prolapse 13
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There is growing consensus that vaginal mesh should nei-
ther be used in every prolapse case nor should it be aban-
doned, as it does have a place in the management of POP.29
There are several factors that determine success, failure,
or risk of complications. The device is one that may be
responsible for complications. It is hypothetically possible
that certain local biochemical factors such as matrix me-
talloproteinase may play a role in the recurrence of prolapse
and also vaginal healing.30 Surgical technique and experi-
ence have been increasingly shown to influence outcomes,
and are among the most critical factors for success.31
Nevertheless, and most important, in an unclean environ-
ment, which the vagina presents, the implantation of foreign
material exposes the patient to risks beyond that of autologous
tissue repairs, which are by definition native to that patient.
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